<DOC>
	<DOCNO>NCT00300781</DOCNO>
	<brief_summary>The purpose study learn whether neratinib safe effective treat woman advance HER2+ ( human epidermal growth factor 2 ) breast cancer .</brief_summary>
	<brief_title>Study Evaluating HKI-272 ( Neratinib ) In Subjects With Advanced Breast Cancer</brief_title>
	<detailed_description>Arm A : HER2 gene amplification disease progression follow least 6 week standard dos Herceptin ; Arm B : HER2 gene amplification prior Herceptin HER2-targeted treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Pathologic diagnosis breast cancer current stage IIIB , IIIC , IV Progression follow least 6 week standard dos Herceptin ( Arm A ) Overexpression HER2 Tumor tissue available adequate analysis screen At least one measurable lesion Prior treatment Herceptin ( Arm B ) More 4 prior cytotoxic chemotherapy regimens Subjects bone skin site measurable disease Inadequate cardiac function Major surgery , chemotherapy , radiotherapy , investigational agent cancer therapy within 1 week treatment day 1 Active central nervous system metastases Pregnant breastfeed woman Inability swallow HKI272 capsule</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>phase 2</keyword>
	<keyword>HER2+ breast cancer</keyword>
	<keyword>monotherapy neratinib</keyword>
</DOC>